Baird Maintains Outperform on Boston Scientific, Lowers Price Target to $75

Benzinga Newsdesk www.benzinga.com Negative 93.0%

Neg 93% Neu 0% Pos 0%

Baird analyst David Rescott maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $78 to $75.